Sp185

A 56 MALE ON TREATMENT FOR MELANOMA WITH ELEVATED LIVER ENZYMES

Date
May 6, 2023
Explore related products in the following collection:

Society: AGA

This session proposed to cover common GI consults on management of patients with liver disease seen at both community and academic centers. Case based presentations on common scenarios such as elevated liver enzymes, autoimmune hepatitis, drug induced liver injury, acute kidney injury in cirrhosis, portal venous thrombosis in cirrhosis, and jaundice in a patient with alcohol-associated liver disease will outline an approach to diagnosis, discussing differential diagnosis, therapeutic options covering rationale for choosing specific options in different clinical settings. LIVE STREAM SESSION

Presenter


Tracks

Related Products

Thumbnail for HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for INTRODUCTION
INTRODUCTION
SOCIETY: AGA
Thumbnail for PANEL DISCUSSION
PANEL DISCUSSION
This session proposed to cover common GI consults on management of patients with liver disease seen at both community and academic centers…
Thumbnail for ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…